As a leading research-driven pharmaceutical company, Laurus Labs aims to improve the quality of life for millions around the world

We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with 9 of the world’s top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.

Continuous innovation is the lifeblood of our business. Therefore, we undertake dedicated R&D in areas that have significant growth potential. We filed 230 patents in which we own 69 patents. We have commercialised 59 products since inception across four distinct business units: Generics API, Generics FDF, Ingredients and Synthesis.

As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.

Annual Report

We are making great progress on our strategic goals. See our latest annual report.

Download




Discover more about Laurus Labs

We are a science-led company at our core. We push back the frontiers of science to serve the needs of humanity. Our state-of-the-art research labs enable us to produce new cures to some of the most challenging diseases. With our manufacturing facilities, we cracked the code of creating high-quality and affordable medicines. Our facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. Our strong R&D and API manufacturing capabilities are enabling us to grow rapidly. We are also one of the most-admired companies to work for in the pharmaceutical sector.



Timeline

2018

Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.
Incorporated a subsidiary in Germany.
Unit 2-Formulations, inspected by USFDA with Zero 483 observations.
Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
Certified as Great Place to Work for the year 2018.

2017

Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)
Successful WHO inspection of Units 1, 2 & 3
Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations

2016

Successful USFDA inspection of the kilo-lab facility at our R&D Centre
Received approval from BfArM Germany for Unit 2 at Vishakhapatnam
Crossed INR 15 billion in revenues
Filed first ANDA with the USFDA and first dossier with the WHO

2015

Commenced commercial operations at Unit 3, Visakhapatnam
Acquired 27% stake in Sriam Labs Private Limited, Hyderabad
Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites

2014

Acquired 135 acres in Visakhapatnam for expansion
Received an investment of INR 3000 million from Bluewater
Commenced construction of Unit 2
Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary

2013

Crossed INR 10 billion in revenues
Received WHO approval for Unit-I

2012

Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and
Secondary acquisition of Aptuit’s majority stake along with additional investments by one of our promoters

2011

Received USFDA and KFDA certification for our R&D Centre
Received KFDA certification for Unit 1

2010

Received USFDA, TGA and UK MHRA certification for the Unit 1, Vishakhapatnam

2009

DSIR recognised our R&D Centre
Commercialised four nutritional fine chemicals
Launched first product in Europe
Entered into a license agreement with an international organisation and a multinational company to manufacture and sell our products in the ARV segment

2008

Filed our first-ever Drug Master File
Commenced operations at Unit-I
Supplied company’s first product to the US

2007

Set up API manufacturing facility Unit-I at Visakhapatnam
Secured investment from Aptuit Singapore of INR 1.02 billion
Executed manufacturing and services agreements with three multinational companies
Commenced operations at our R&D Centre

2006

Set up our R&D Centre at IKP, Knowledge Park, Hyderabad
Signed a term sheet with a leading Indian pharmaceutical company for oncology APIs
Filed our first patent application

2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006

Our key achievements


55+

State-of-the-art R & D labs in India and the US

90+

APIs manufactured at 8 manufacturing facilities

₹ 220+

Billion in annual revenues in FY18

800+

Research scientists out of a total workforce of over 2600

200+

Customers across 56 countries

230

Patents filed and 69 patents granted

3+

Million liters of reactor capacity

8

Manufacturing Facilities